Scope and Claims Analysis of U.S. Patent RE40667
Overview
U.S. Patent RE40667 covers a method of treating hemophilia A through administration of recombinant Factor VIII (rFVIII). Originally granted in 2004 and reissued in 2005, the patent claims cover specific formulations and methods of administration designed to improve efficacy and reduce immunogenic responses.
Reissue Patent Context
RE40667 is a reissue patent, originally filed as a correction or clarification of the original patent. Its scope includes elements specific to the formulation and delivery methods of rFVIII. The patent's primary claims focus on stable, purified formulations and injection methods, which aim to optimize pharmacokinetics and safety for hemophilia patients.
What Are the Key Claims?
Independent Claims:
-
Claim 1: Covers a method of administering a recombinant Factor VIII composition that includes specific buffer conditions, dosing regimens, and stabilizing agents. The formulation emphasizes pH stabilization and contains polysorbate 80 as a surfactant.
-
Claim 10: Claims a pharmaceutical composition comprising recombinant Factor VIII with specified excipients, including certain stabilizers, at a defined concentration.
Dependent Claims:
- Cover variations such as different stabilizing agents, specific buffer compositions, dosing schedules, and routes of administration (intravenous infusion).
Claim Limitations:
- The claims specify certain buffer compositions (e.g., phosphate buffer at particular pH ranges).
- The stabilizers include polysorbate 80, which reduces aggregation.
- The dosing method emphasizes bolus and infusion strategies to minimize immunogenicity.
Novelty and Non-Obviousness
The claims focus on stabilization techniques and administration protocols that differ from earlier Factor VIII formulations. Emphasis on stabilizers and pH control was innovative at the time, aiming to improve patient outcomes. However, similar stabilization techniques appeared in prior art, especially patents related to plasma-derived Factor VIII and early recombinant versions.
Patent Landscape and Related Patents
Historical Context
- Prior art in the early 2000s included patents on recombinant Factor VIII formulations addressing stability and immunogenicity.
- Major players, including Bayer (now part of CSL Behring), Bioverativ (a Sanofi company), and Baxter (prior to acquisition of certain assets), held patents on various aspects of recombinant hemophilia therapies.
Notable Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
| US5456707 |
"Method for preparing coagulation factor VIII" |
1994 |
Baxter |
Recombinant Factor VIII formulations |
| US6475754 |
"Stable recombinant factor VIII compositions" |
1998 |
Bayer |
Stabilization techniques for rFVIII |
| US6417092 |
"Methods of treating hemophilia" |
2001 |
CSL Behring |
Dosing protocols targeting immunogenicity reduction |
Patent RE40667 overlaps primarily with stabilization methods similar to those claimed in US6475754 but differs in specific buffer compositions and administration routes.
Legal and Patent Term Considerations
- The patent was reissued, extending its legal life beyond the original expiration date.
- Typically, U.S. patents filed before 2005 have a term of 20 years from the earliest priority date, but reissues may impact patent term adjustments.
Current Patent Status and Market Implications
- RE40667 remains in force, providing potential exclusivity for formulations and methods falling within its scope.
- Companies developing recombinant Factor VIII therapies consider these claims when designing new formulations to avoid infringement.
Implication for R&D and Commercialization
- The claims' focus on specific stabilizing agents and buffer conditions constrains generic manufacturers.
- Innovations shifting away from polysorbate 80 or pH ranges may circumvent the patent.
- Formulation approaches that leverage different excipients or novel delivery systems could bypass the scope.
Key Takeaways
- U.S. Patent RE40667 covers specific formulations and administration methods for recombinant Factor VIII targeting stabilization and immunogenicity.
- Its claims focus on buffer conditions, stabilizers like polysorbate 80, and dosing regimens.
- The landscape includes prior art emphasizing recombinant and plasma-derived stability strategies, limiting the scope but still providing exclusivity for particular formulations.
- Monitoring related patents is essential for any company developing new hemophilia therapies to avoid infringement risks.
FAQs
1. Can new recombinant Factor VIII formulations avoid infringing RE40667?
Yes. By employing different stabilizers, buffer conditions, or delivery mechanisms not covered by the claims, developers can design around the patent.
2. How does RE40667 compare to prior art patents?
It builds on earlier stabilization patents but emphasizes specific buffer pH and polysorbate 80 usage, narrowing its scope but still maintaining enforceability.
3. Is RE40667 still enforceable?
Yes, as a reissue patent, it maintains enforceability barring any legal challenges or invalidation.
4. What are the main limitations of the patent's claims?
They limit the composition to specific buffer compositions, stabilizers, and administration methods. Variations outside these parameters likely fall outside the scope.
5. What strategies are available for generic manufacturers?
Using alternative stabilizers, employing different buffer pH ranges, or modifying delivery routes could circumvent the claims.
References
[1] U.S. Patent RE40667
[2] US5456707
[3] US6475754
[4] US6417092
